SEATTLE, Aug. 6 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. today announced it plans to issue earnings results for the second quarter and six months ended 2007 after the close of market on August 13, 2007. The Company’s earnings conference call will take place the same day at 2 p.m. Pacific Time; 5 p.m. Eastern Time.
The live event will be available from Trubion’s website at http://investors.trubion.com/events.cfm, or by calling 1-800-361-0912 or 1-913-981-5559. A replay of the discussion will be available after the call from Trubion’s website or by calling 1-888-203-1112 or 1-719-457-0820, and entering 4636344. The telephone replay will be available through August 17, 2007.
About Trubion
Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The Company’s product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP(TM) custom drug assembly technology. In less than 24 months, the Company designed, developed and submitted to the FDA an Investigational New Drug application for its lead product candidate, TRU-015, which is currently being tested in a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the Company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion’s TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Subject to satisfactory completion of preclinical testing of TRU-016, the Company expects to file an IND for TRU-016 in the second half of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit http://www.trubion.com.
TRBN-G Jim DeNike Senior Director, Corporate Communication Trubion Pharmaceuticals, Inc. 1-206-838-0500 jdenike@trubion.comhttp://www.trubion.com
Trubion Pharmaceuticals, Inc.
CONTACT: Jim DeNike, Senior Director, Corporate Communication of TrubionPharmaceuticals, Inc., +1-206-838-0500, jdenike@trubion.com
Web site: http://www.trubion.com/
